ERBB2 and breast carcinoma: The monoclonal antibody trastuzumab was the first agent developed for HER2 targeting and can improve outcomes among women with HER2-positive breast cancer.581 In GC, the addition of trastuzumab to standard chemotherapy of HER2-positive GC may increase the survival of the patients.40